October 24, 2012 / 6:06 AM / in 5 years

BRIEF-Elan says Q3 revenues up 10 pct

DUBLIN, Oct 24 (Reuters) - Elan Corporation PLC : * Adjusted EBITDA was 38% higher, driven by a 13% increase in tysabri patient

numbers. * Re-affirming our full-year guidance of adjusted EBITDA greater than $200

million * Total revenue for the third quarter of 2012 increased by 10% to $306.6

million * Tysabri global in-market net sales grew by 3% to $403.8 million * Number of patients on tysabri increased by 13% to approximately 71,100

patients * Net loss from continuing operations was $216.2 million versus net income $3.5

million in Q3 2011 * Charges of $111.3 million principally related to restructuring the Elan

business

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below